GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regentis Biomaterials Corp (NAS:RGNT) » Definitions » 12-1 Month Momentum %

Regentis Biomaterials (Regentis Biomaterials) 12-1 Month Momentum % : N/A% (As of Jun. 18, 2024)


View and export this data going back to 2050. Start your Free Trial

What is Regentis Biomaterials 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-06-18), Regentis Biomaterials's 12-1 Month Momentum % is N/A%.

The industry rank for Regentis Biomaterials's 12-1 Month Momentum % or its related term are showing as below:

RGNT's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -19.11
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Regentis Biomaterials's 12-1 Month Momentum %

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regentis Biomaterials's 12-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's 12-1 Month Momentum % falls into.



Regentis Biomaterials  (NAS:RGNT) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regentis Biomaterials  (NAS:RGNT) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Regentis Biomaterials 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Regentis Biomaterials's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regentis Biomaterials (Regentis Biomaterials) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12 Ha’ilan Street, P.O. Box 260, Northern Industrial Zone, Or-Akiva, ISR, 306000
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Regentis Biomaterials (Regentis Biomaterials) Headlines

No Headlines